-
Announcement of the State Food and Drug Administration on Revising the Instructions for Use of Misoprostol Tablets in Obstetrics and Gynecology (No. 29 of 2021)
Time of Update: 2021-07-08
The marketing authorization holder of this product shall submit a supplementary application for the revision of the label in accordance with the "Administrative Measures on Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the label for misoprostol tablets in obstetrics and gynecology (see attachment), in 2021 Before May 24, report to the Drug Evaluation Center of the State Drug Administration or the provincial drug regulatory authority for the record .
-
Announcement of the State Food and Drug Administration on the conversion of Wei'an capsules to non-prescription drugs (No. 19 of 2021)
Time of Update: 2021-07-08
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
doc of the National Medical Products Administration Annex 2 of the Announcement No.
-
Announcement of the State Food and Drug Administration on the conversion of Chaiyin Granules into over-the-counter drugs (No. 134 of 2020)
Time of Update: 2021-07-08
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
Templates for non-prescription drug instructions State Food and Drug Administration December 9, 2020 Announcement No.
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Sodium Ferulate Injection (No. 43 of 2021)
Time of Update: 2021-07-08
In order to further protect the safety of public medication, the State Drug Administration has decided to revise the instructions for sodium ferulate injection preparations . The relevant matters a
-
Announcement of the State Food and Drug Administration on approving the Chongqing Municipal Drug Administration to increase the registration function for the first import of chemical drugs (No. 21 of 2021
Time of Update: 2021-07-08
Agree to increase the registration function of the first import of chemical drugs by the Chongqing Municipal Drug Administration .
From the date of issuance of this announcement, the Chongqing Municipal Drug Administration can handle the registration procedures for the first import of chemical drugs .
-
Announcement of the State Food and Drug Administration on the conversion of Guifu Dihuang Granules into over-the-counter drugs (No. 52 of 2021)
Time of Update: 2021-07-08
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
Templates for non-prescription drug instructions State Food and Drug Administration April 7, 2021 Announcement No.
-
Children cannot "feed" cold medicines randomly, 14 kinds of medicines for children were named by the Drug Administration
Time of Update: 2021-07-08
Reporter | Yuan YimingEdit | Xie Xin On April 23, the official website of the State Food and Drug Administration announced the "Announcement on Revising the Drug Inserts of 14 Varieties of Paracetamol and Mami Oral Solution" (hereinafter referred to as the "Announcement"), restricting and warning on the use of several cold medicines for children .
-
Announcement of the State Food and Drug Administration on Issuing 3 Supplementary Inspection Methods including the Supplementary Inspection Methods for Rosin Acid in Gentongping Tablets (No. 47 of 2021)
Time of Update: 2021-07-08
Supplementary inspection method for ginsenoside F11 inspection item in Xiaomi suppository State Food and Drug Administration March 30 2021 Announcement No.
doc of the National Medical Products Administration Announcement No.
47 of 2021 Annex 2 of the National Medical Products Administration.
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Liuwei Dihuang Preparations (No. 23 of 2021)
Time of Update: 2021-07-08
The marketing authorization holders of all the above-mentioned drugs shall revise the inserts in accordance with the relevant regulations such as the "Administrative Measures for Drug Registration" and the corresponding insert revision requirements (see appendix), and report to the provincial drug supervision and administration department for record before May 2, 2021 .
-
Announcement of the State Food and Drug Administration on the cancellation of 226 drug registration certificates including bromelain enteric-coated tablets (No. 27 of 2021)
Time of Update: 2021-07-08
According to the "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China" and the "Administrative Measures for Drug Registration", the State Drug Administ
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Mouse Nerve Growth Factor for Injection (No. 45 of 2021)
Time of Update: 2021-07-08
The marketing authorization holders of the above-mentioned drugs should be submitted to the provincial drug supervision and management before June 17, 2021 in accordance with the requirements for the revision of the insert for mouse nerve growth factor for injection in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations.
-
Mao Qun'an, Director of the Health Commission: Looking forward to the "Internet + Medical" new business format to discover medical needs sooner
Time of Update: 2021-07-08
On April 19, at the "Future Medical Ecology" sub-forum of the Boao Forum for Asia 2021 Annual Conference, Mao Qun'an, Director of the Department of Planning, Development and Informatization of the National Health Commission, said that the current policy level is to encourage and support "Internet + Medical Care".
-
Medical insurance negotiation drugs will establish a "dual-channel" mechanism. Will the innovative drugs entering medical insurance disappear?
Time of Update: 2021-07-07
The "Opinions" explained that the "dual channel" refers to the two channels of designated medical institutions and designated retail pharmacies to meet the needs of negotiated drug supply guarantees and clinical use, and incorporate them into the medical insurance payment mechanism .
-
Notice of the State Drug Administration on Publicizing the List of the Second Batch of Key Laboratories
Time of Update: 2021-07-07
During the publicity period, if there is any objection to the publicity object, it can be reported to the State Drug Administration .
-
Announcement of the State Drug Administration on Protected Varieties of Traditional Chinese Medicines (Extended Protection Period No. 6) (No. 146 of 2020)
Time of Update: 2021-07-07
According to Article 16 of the Regulations on the Protection of Traditional Chinese Medicines and related regulations, after review by members organized by the National Traditional Chinese Medicines Protection Review Committee, the State Drug Administration approved: The protected varieties of ginkgo ketone ester dripping pills produced by Zhejiang Jiuxu Pharmaceutical Co.
State Food and Drug Administration December 28, 2020
-
Announcement of the State Food and Drug Administration on the conversion of three kinds of drugs including Siji Antiviral Mixture into over-the-counter drugs (No. 137 of 2020)
Time of Update: 2021-07-07
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
Templates for non-prescription drug instructions State Food and Drug Administration Announcement No.
-
Announcement of the State Food and Drug Administration on the cancellation of registration certificates for phenolphthalein tablets and phenolphthalein buccal tablets (No. 6 of 2021)
Time of Update: 2021-07-07
According to Article 83 of the "Drug Administration Law of the People's Republic of China", the State Drug Administration organized a post-marketing evaluation of phenolphthalein tablets and phenolphthalein lozenges.
Attachment: List of manufacturers of phenolphthalein tablets and phenolphthalein lozenges State Food and Drug Administration January 8, 2021 Annex to Announcement No.
-
Announcement of the State Food and Drug Administration on the issuance of 3 supplementary inspection methods including the supplementary inspection method for auramine O inspection items in Fuke Tiaojing Tablets (No. 15 of 2020
Time of Update: 2021-07-07
According to the relevant provisions of the "Drug Administration Law of the People's Republic of China" and its implementation regulations, "Supplementary Inspection Method for Auramine O Inspection
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Benzbromarone Oral Preparations (No. 150 of 2020)
Time of Update: 2021-07-07
In order to further protect the safety of public medication, the State Drug Administration has decided to revise the instructions for benzbromarone oral preparations .
Attachment: Requirements for the revision of the instructions for benzbromarone oral preparations State Food and Drug Administration December 29, 2020
-
Notice of Drug Quality Sampling Inspection of Shandong Provincial Drug Administration (No. 8 of 2020)
Time of Update: 2021-07-07
3. For non-compliant products and corresponding production and operation enterprises and units, the relevant drug regulatory authorities shall strengthen supervision, supervise them to find out the cause of the problem, formulate and implement rectification measures, and effectively eliminate hidden risks .
